Neuphoria Therapeutics Inc (NEUP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.70 (-0.40%), Market cap $0.03B, 52-week low–high $3.72 ~ $20.00.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indication
Financial statements, price targets, institutional (13F) holdings and related news for Neuphoria Therapeutics Inc are updated in real time on BlackAll Trade.
Neuphoria Therapeutics Inc trades at $3.70 (-0.40%). Real-time quotes and charts are available on BlackAll Trade.
Neuphoria Therapeutics Inc has a market cap of about $0.03B.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Austral